QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
QQQ   284.19 (-0.08%)
AAPL   116.87 (-0.54%)
MSFT   214.80 (+0.07%)
FB   278.73 (+4.17%)
GOOGL   1,585.99 (+2.25%)
AMZN   3,184.94 (-1.00%)
TSLA   422.64 (+0.17%)
NVDA   540.99 (-0.88%)
BABA   307.97 (-0.59%)
CGC   19.49 (+3.23%)
GE   7.32 (-0.27%)
MU   53.31 (-0.41%)
AMD   79.20 (-2.89%)
T   26.72 (-0.15%)
F   7.85 (+1.42%)
ACB   4.85 (+6.36%)
GILD   60.21 (-0.56%)
NFLX   489.05 (-6.92%)
BA   163.86 (-2.02%)
NIO   27.86 (-0.36%)
BAC   24.05 (-0.37%)
Log in
OTCMKTS:CBWTF

Auxly Cannabis Group Competitors

$0.17
-0.10 (-36.87 %)
(As of 10/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.17
Now: $0.17
$0.28
50-Day Range
$0.09
MA: $0.13
$0.27
52-Week Range
$0.08
Now: $0.17
$0.59
Volume5.40 million shs
Average Volume1.03 million shs
Market Capitalization$109.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.62

Competitors

Auxly Cannabis Group (OTCMKTS:CBWTF) Vs. SPHRY, AVXL, LUNA, PIRS, ELOX, and BIOQ

Should you be buying CBWTF stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Auxly Cannabis Group, including STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), and BIOQUAL (BIOQ).

STARPHARMA HOLD/S (OTCMKTS:SPHRY) and Auxly Cannabis Group (OTCMKTS:CBWTF) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares STARPHARMA HOLD/S and Auxly Cannabis Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STARPHARMA HOLD/S$4.40 million96.93$-9,860,000.00N/AN/A
Auxly Cannabis Group$6.29 million17.47$-77,300,000.00N/AN/A

STARPHARMA HOLD/S has higher earnings, but lower revenue than Auxly Cannabis Group.

Profitability

This table compares STARPHARMA HOLD/S and Auxly Cannabis Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STARPHARMA HOLD/SN/AN/AN/A
Auxly Cannabis Group-531.54%-47.44%-28.11%

Analyst Ratings

This is a breakdown of recent ratings for STARPHARMA HOLD/S and Auxly Cannabis Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STARPHARMA HOLD/S0000N/A
Auxly Cannabis Group00203.00

Auxly Cannabis Group has a consensus price target of $0.40, suggesting a potential upside of 133.64%. Given Auxly Cannabis Group's higher probable upside, analysts plainly believe Auxly Cannabis Group is more favorable than STARPHARMA HOLD/S.

Risk & Volatility

STARPHARMA HOLD/S has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Comparatively, Auxly Cannabis Group has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

STARPHARMA HOLD/S beats Auxly Cannabis Group on 6 of the 10 factors compared between the two stocks.

Auxly Cannabis Group (OTCMKTS:CBWTF) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Auxly Cannabis Group and Anavex Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Auxly Cannabis Group-531.54%-47.44%-28.11%
Anavex Life SciencesN/A-101.10%-81.05%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Comparatively, 19.8% of Anavex Life Sciences shares are held by institutional investors. 12.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Anavex Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Auxly Cannabis Group00203.00
Anavex Life Sciences00503.00

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Anavex Life Sciences has a consensus price target of $12.00, indicating a potential upside of 133.01%. Given Auxly Cannabis Group's higher probable upside, equities analysts plainly believe Auxly Cannabis Group is more favorable than Anavex Life Sciences.

Valuation and Earnings

This table compares Auxly Cannabis Group and Anavex Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Auxly Cannabis Group$6.29 million17.47$-77,300,000.00N/AN/A
Anavex Life SciencesN/AN/A$-26,300,000.00($0.50)-10.30

Anavex Life Sciences has lower revenue, but higher earnings than Auxly Cannabis Group.

Summary

Anavex Life Sciences beats Auxly Cannabis Group on 6 of the 11 factors compared between the two stocks.

Auxly Cannabis Group (OTCMKTS:CBWTF) and Luna Innovations (NASDAQ:LUNA) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Auxly Cannabis Group and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Auxly Cannabis Group-531.54%-47.44%-28.11%
Luna Innovations4.93%7.50%5.86%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Comparatively, 44.0% of Luna Innovations shares are held by institutional investors. 11.2% of Luna Innovations shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Luna Innovations, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Auxly Cannabis Group00203.00
Luna Innovations01102.50

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Luna Innovations has a consensus price target of $8.00, indicating a potential upside of 16.79%. Given Auxly Cannabis Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Auxly Cannabis Group is more favorable than Luna Innovations.

Valuation and Earnings

This table compares Auxly Cannabis Group and Luna Innovations' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Auxly Cannabis Group$6.29 million17.47$-77,300,000.00N/AN/A
Luna Innovations$70.52 million2.99$5.34 million$0.1740.29

Luna Innovations has higher revenue and earnings than Auxly Cannabis Group.

Summary

Luna Innovations beats Auxly Cannabis Group on 9 of the 13 factors compared between the two stocks.

Auxly Cannabis Group (OTCMKTS:CBWTF) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Auxly Cannabis Group and Pieris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Auxly Cannabis Group-531.54%-47.44%-28.11%
Pieris Pharmaceuticals-25.90%-35.00%-11.81%

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. Comparatively, 65.5% of Pieris Pharmaceuticals shares are held by institutional investors. 5.7% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Pieris Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Auxly Cannabis Group00203.00
Pieris Pharmaceuticals00303.00

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Pieris Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 224.83%. Given Pieris Pharmaceuticals' higher probable upside, analysts plainly believe Pieris Pharmaceuticals is more favorable than Auxly Cannabis Group.

Valuation and Earnings

This table compares Auxly Cannabis Group and Pieris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Auxly Cannabis Group$6.29 million17.47$-77,300,000.00N/AN/A
Pieris Pharmaceuticals$46.28 million2.44$-25,470,000.00($0.56)-3.85

Pieris Pharmaceuticals has higher revenue and earnings than Auxly Cannabis Group.

Summary

Pieris Pharmaceuticals beats Auxly Cannabis Group on 10 of the 12 factors compared between the two stocks.

Auxly Cannabis Group (OTCMKTS:CBWTF) and Eloxx Pharmaceuticals (OTCMKTS:ELOX) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Auxly Cannabis Group and Eloxx Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Auxly Cannabis Group00203.00
Eloxx Pharmaceuticals02302.60

Auxly Cannabis Group currently has a consensus price target of $0.40, indicating a potential upside of 133.64%. Eloxx Pharmaceuticals has a consensus price target of $5.80, indicating a potential upside of 107.14%. Given Auxly Cannabis Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Auxly Cannabis Group is more favorable than Eloxx Pharmaceuticals.

Valuation and Earnings

This table compares Auxly Cannabis Group and Eloxx Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Auxly Cannabis Group$6.29 million17.47$-77,300,000.00N/AN/A
Eloxx PharmaceuticalsN/AN/AN/AN/AN/A

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Auxly Cannabis Group.

Profitability

This table compares Auxly Cannabis Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Auxly Cannabis Group-531.54%-47.44%-28.11%
Eloxx PharmaceuticalsN/AN/AN/A

Insider & Institutional Ownership

0.0% of Auxly Cannabis Group shares are held by institutional investors. 44.0% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals beats Auxly Cannabis Group on 5 of the 9 factors compared between the two stocks.

Auxly Cannabis Group (OTCMKTS:CBWTF) and BIOQUAL (OTCMKTS:BIOQ) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares Auxly Cannabis Group and BIOQUAL's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Auxly Cannabis Group$6.29 million17.47$-77,300,000.00N/AN/A
BIOQUAL$46.36 million1.34$4.23 millionN/AN/A

BIOQUAL has higher revenue and earnings than Auxly Cannabis Group.

Profitability

This table compares Auxly Cannabis Group and BIOQUAL's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Auxly Cannabis Group-531.54%-47.44%-28.11%
BIOQUAL9.13%16.17%8.85%

Analyst Ratings

This is a breakdown of current ratings for Auxly Cannabis Group and BIOQUAL, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Auxly Cannabis Group00203.00
BIOQUAL0000N/A

Auxly Cannabis Group currently has a consensus price target of $0.40, suggesting a potential upside of 133.64%. Given Auxly Cannabis Group's higher probable upside, analysts plainly believe Auxly Cannabis Group is more favorable than BIOQUAL.

Institutional & Insider Ownership

0.0% of Auxly Cannabis Group shares are owned by institutional investors. 39.2% of BIOQUAL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Auxly Cannabis Group has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, BIOQUAL has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500.

Summary

BIOQUAL beats Auxly Cannabis Group on 7 of the 12 factors compared between the two stocks.


Auxly Cannabis Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SPHRY
STARPHARMA HOLD/S
0.5$10.59-1.0%$426.51 million$4.40 million0.00
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.4$5.15-0.8%$309.98 millionN/A-12.26Analyst Report
Heavy News Reporting
Luna Innovations logo
LUNA
Luna Innovations
1.5$6.85-3.4%$210.97 million$70.52 million62.28
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$2.16-8.4%$112.92 million$46.28 million-6.73
Eloxx Pharmaceuticals logo
ELOX
Eloxx Pharmaceuticals
1.3$2.80-0.7%$112.39 millionN/A0.00Heavy News Reporting
BIOQ
BIOQUAL
1.1$70.00-6.4%$62.30 million$46.36 million14.77
BASI
Bioanalytical Systems
1.1$5.27-1.3%$57.91 million$43.62 million-22.91Heavy News Reporting
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$3.16-0.3%$41.13 million$1.11 million0.00High Trading Volume
Heavy News Reporting
HPPI
HedgePath Pharmaceuticals
0.4$0.06-0.0%$20.38 millionN/A0.00High Trading Volume
TENX
Tenax Therapeutics
1.3$1.21-0.8%$15.27 millionN/A-0.89
VBIO
Vitality Biopharma
0.5$0.17-0.0%$8.60 million$260,000.000.00
USRM
US Stem Cell
0.6$0.01-0.0%$3.48 million$6.70 million0.00
PRTX
Protalex
0.7$0.00-0.0%$10,000.00N/A0.00
ALGXY
ALGAE TEC LTD/S
0.4$0.00-0.0%$0.00$2.05 million0.00
RPBC
Redpoint Bio
0.5$0.00-0.0%$0.00N/A0.00
This page was last updated on 10/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.